This study will explore how safe and effective a new drug, LY3962673, is for people with certain types of cancer. Specifically, it targets cancers with the KRAS G12D mutation, which is a change in the genes that can make cells grow out of control. The study will last about 5 years and will include people with advanced cancers that have spread or cannot be removed by surgery.
People can join this study if they have had at least one round of chemotherapy before and their cancer has the KRAS G12D mutation. Participants should not have serious heart problems or active infections like hepatitis. They should also not have severe side effects from previous treatments.
- This study will last approximately 5 years.
- Participants will receive a new drug, LY3962673, alone or with other chemotherapy drugs.
- Participants need to have specific mutations in their cancer and have previously undergone chemotherapy.
Joining a study like this can help doctors learn more about treating KRAS G12D-mutant cancers and may offer potential benefits to participants, but it may also involve risks and side effects from the treatment.